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Abortive infectionThe lymphotropic herpesvirus KSHV principally infects B cells in vivo and is linked to several human B cell
lymphoproliferative syndromes. Here we examine the susceptibility of primary tonsillar lymphocytes to
infection by a recombinant KSHV (rKSHV.219) that constitutively expresses GFP. At anMOI of ~1, ca. 5–10% of
CD19+ B cells became GFP-positive. Surprisingly, in the same culture many more T cells became infected.
However, in contrast to isolated B cells, isolated infected T cells did not support correct viral transcription and
did not produce infectious virus, indicating the presence of one or more post-entry blocks to lytic KSHV
replication in T cells. No immortalization or transformation has yet been observed in either B or T cells. These
results afﬁrm the feasibility of studying KSHV infection in primary lymphoid cells, and help to rationalize the
detection of KSHV DNA in rare human T cell lymphomas in vivo.g).
l rights reserved.© 2010 Elsevier Inc. All rights reserved.Introduction
Kaposi's sarcoma-associated herpesvirus (KSHV) is the newest
addition to human herpesvirus family. Initially identiﬁed in 1994 on
the basis of its association with Kaposi's sarcoma, an endothelial
neoplasm (Chang et al., 1994; Chuck et al., 1996; and reviewed in
Ganem, 2006), it is now classiﬁed as a member of the lymphotropic
(γ) herpesvirus subfamily together with Epstein–Barr virus (EBV)
and its simian relatives, Herpesvirus saimiri (HVS) and Rhesus
rhadinovirus (RRV). Consistent with this classiﬁcation, KSHV DNA
can be found in circulating B cells in infected patients (Ambroziak
et al., 1995; Mesri et al., 1996). Moreover, the virus also causes two B
cell lymphoproliferative disorders: primary effusion lymphoma (PEL)
and multicentric Castleman's diseases (MCD) (Carbone and Gloghini,
2008; Cesarman et al., 1995, 1996; Nador et al., 1995). B cells derived
from PEL were the ﬁrst cultured cells in which KSHV latency was
observed, and remain the most widely studied experimental system
for the molecular analysis of latent gene expression (Mesri et al.,
1996; Renne et al., 1996). However, despite this clear evidence of
lymphotropism, all established B cell lines tested to date are resistant
to KSHV infection in culture (Bechtel et al., 2003; Blackbourn et al.,
2000; Renne et al., 1998), as are resting peripheral bloodmononuclear
cells. This failure to infect B cells is all the more striking given theready infection of most other adherent cell lines in vitro (Bechtel et al.,
2003; Vieira et al., 2001). Why this is so remains a mystery, and one
that has greatly impeded our understanding of the relationship of
KSHV infection to B cell function, survival and transformation.
Primary B cells from peripheral blood have recently been shown to
be susceptible to KSHV infection if they are ﬁrst activated by CD40L
and IL-4 (Rappocciolo et al., 2008). We set out to develop a different
system for the infection of primary lymphoid elements by KSHV. We
chose to focus on cells derived from human tonsils, for two reasons:
(i) they can be directly accessed by the oral route and their surgical
removal is frequently carried out, assuring adequate tissue availabil-
ity; and (ii) the main source of infectious KSHV in infected humans is
saliva, and tonsillar infection in vivo is presumed to be one important
source of this infectivity (infected pharyngeal epithelium being the
other). Therefore, tonsillar infection has likely relevance to the in vivo
setting. Moreover, primary cells derived from tonsils have been
successfully employed to cultivate other lymphotropic viruses,
including HIV (Glushakova et al., 1995; Kreisberg et al., 2006),
HHV-6 (Grivel et al., 2003; Roush et al., 2001), and EBV (Aman et al.,
1985; Babcock and Thorley-Lawson, 2000; Strowig et al., 2008).
Two types of culture systems can be derived from human tonsils.
Blocks of intact tonsils, which retain the three dimensional structure
of the lymphoid organ, can be cultured (Glushakova et al., 1995; Penn
et al., 1999), but it is difﬁcult to expose all cells in this type of explant
to an infectious inoculum, and quantitation of the resulting infection
can be problematic. Alternatively, dispersed cell suspensions can be
made from the tonsil and placed directly into culture (to form
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2005; Eckstein et al., 2001). These HLAC cultures preserve most of the
cell types of the organ in their correct ratios and are more readily
infected ex vivo. More importantly, they are amenable to experimental
manipulations: e.g. deletion of cell subsets, activation of cell subsets
with appropriate ligands, staining with antibodies, analysis of
apoptosis, etc. For this reason, we have chosen to employ HLAC
explants to explore lymphoid infection by KSHV. We show here that
this system allows efﬁcient and reproducible infection of lymphocytes
by KSHV, and treatment of the cultures with HDAc inhibitors results in
enhanced production of infectious virus. To our surprise, we found
that T cells as well as B cells can be infected, with both CD4 and CD8
subsets proving susceptible to KSHV entry. Virus entry into B cells is
inefﬁcient, with only 5–10% of B cells displaying GFP expression; by
contrast, large numbers of T cells can support viral entry. However,
infected T cells do not support production of infectious virus, either
spontaneously or after treatment with HDAc inhibitors, indicating
that T cell infection is abortive. Neither B nor T cells are immortalized
following KSHV exposure, though infected B cells do show modest
prolongation of their lifespan in culture.
Results
rKSHV.219 infects primary lymphoid cells
To investigate whether rKSHV.219 infects tonsillar cells, recombi-
nant virus stocks were prepared and titrated on QBI293A cells as
described in Materials and methods. To study speciﬁc infection of
KSHV in tonsillar cells, polybrene was not included in infection
cultures as it is known to enhance KSHV infection non-speciﬁcally
(Inoue et al., 2003; Lagunoff et al., 2002). We prepared 2 million
tonsillar cells as an HLAC culture as described in Materials and
methods; these cells were then infected with 1.4×106 IU (MOI=0.7)
of rKSHV.219. Cells were analyzed at 48 h post infection (hpi) for GFP
expression by ﬂow cytometry, gating on CD19-positive (B) cells or
CD3-positive (T) cells. In a given tonsil, CD19+ B cells account for
60–80% of the cells, while CD3+ T cells represent 20–40% of the cells,
respectively (Fig. 1, left panel). All other cell types, including NK
(CD56+), granulocytes (CD66b+), monocytes (CD14+), and den-
dritic cells (CD11c+ or CD123+), constitute altogether less than 1% of
total tonsillar cells in a given HLAC preparation, making it difﬁcult to
study speciﬁc KSHV infection in these populations. Therefore,
examination of KSHV infectivity in tonsillar cells was focused on B
and T cells.
As shown in Fig. 1A (top left panel), under standard infection
conditions 9.4% of CD19+ cells became GFP+, indicating that they
were infected by rKSHV.219. Surprisingly, primary CD3+ T cells
seemed to be even more susceptible to rKSHV.219 infection than
CD19+ B cells. In the absence of PHA, fully 35.5% of CD3+ T cells were
GFP+ at 48 hpi (bottom left panel). [Note: this assay only measures
viral entry, uncoating and reporter gene expression, and does not
directly address whether the infected cells produce infectious viral
progeny; that issue will be addressed in Fig. 6.] When the cultures
were treated with the polyclonal T cell activator PHA, the fraction of
CD3 cells that scored for GFP increased to 47.6% (Fig. 1A, bottom right
panel) (PHA treatment, as might be expected, did not enhance
susceptibility of B cells to infection; top right panel.). Given that at an
MOI=0.7 some 48% of the culture is expected from Poisson statistics
to be uninfected, this means that approximately 70% of T cells and 18%
of B cells in this experiment were susceptible to infection by KSHV ex
vivo. In other experiments, the percentage of infectable B cells in
tonsillar explants varied from 4% to 10% (Fig. 2 and data not shown).
To analyze which subsets of T cells are infected by rKSHV.219,
tonsillar cells infected at a lower MOI (0.04) were stained with anti-
CD3, anti-CD4 and anti-CD8 antibodies. As shown in Fig. 1B, both CD4
and CD8 T cells became infected. In the absence of PHA stimulation, ca.8% of CD4 cells and 12% of CD8 cells were GFP-positive, and in the
presence of PHA these percentages increased 2- and 3-fold,
respectively. This increased GFP expression reﬂects an enhanced
susceptibility to KSHV infection triggered by PHA exposure: when
PHA was added to tonsillar cells at the time of virus inoculation or
24 h post-inoculation, GFP-positivity was not signiﬁcantly affected
compared to that of the untreated group (data not shown).
The MOI used in these experiments was based on viral infectivity
titers measured in 293 cells, a standard non-lymphoid line known to
be permissive for KSHV (Bechtel et al., 2003). The Poisson distribution
predicts that at MOI=0.04, ca. 4% of cells exposed to virus should
receive one or more infectious virus particles. In the absence of PHA,
we observe that ~2.5% of total lymphoid cells became infected, as
judged by GFP expression. (In the presence of T cell activation, fully
4–5% of the cells in the culture became infected.) At an MOI of 0.7,
conditions under which 48% of cells are expected to be infected,
16–20% of the cells in the HLAC culture became GFP-positive. We
conclude that the speciﬁc infectivity of KSHV for primary lymphoid
cells is ca. 33–50% that observed for cultured 293 cells. Activated T
cells are fully as susceptible to KSHV infection as 293 cells, but B cells
are infected only ~20% as efﬁciently as 293 cells in vitro (at best).
Moreover, we note that the levels of virus-encoded gene expression
per infected cell are lower in primary lymphocytes compared to
established nonlymphoid cell lines. For example, when analyzed
by ﬂow cytometry, the mean ﬂuorescence intensity of GFP in
rKSHV.219-infected 293 cells is typically 20–30 fold higher than
that observed in infected primary tonsillar B or T cells.
Reproducibility of lymphoid infection in HLAC cultures
One limitation of HLAC cultures is that, of necessity, they derive
from diverse, genetically unrelated individuals. To determine how
much individual variation in the patterns of KSHV infection may exist
from prep to prep, we systematically examined the lymphoid targets
of infection in tonsillar cells from 10 individuals, whether untreated or
treated with PHA (10 μg/ml) for 6–12 h. Cells were infected with
rKSHV.219 for 48 h, at MOI=0.04. As shown in Fig. 2, even in the
absence of PHA stimulation, CD8+ T cells were generally infected at
higher levels (13.2%) than CD4+ T (8.3%) or CD19+ B cells (4.6%)
(CD8+ vs CD4+ T cells, p=0.032). PHA stimulation reproducibly
enhanced infectivity in both T cell subsets, with the enhancement
being characteristically larger in CD8-positive cells. Thus, although
cultures do vary somewhat from individual to individual in the
absolute number of cells infected following exposure, the distribution
of infection among the major B and T cell populations is remarkably
reproducible.
KSHV infection does not immortalize either tonsillar B or T cells in HLAC
cultures
To examine the potential consequences of KSHV infection in
lymphocytes, we infected cells and periodically examined them for
several weeks following inoculation. In no case was immortalization
of the culture observed; no stable lines of latently infected cells have
yet emerged from KSHV-infected HLAC cultures. To increase the
sensitivity of detection of rare immortalizing events, we took
advantage of the fact that rKSHV.219 also carries a selectable marker
(for puromycin-resistance). Tonsillar cells were infected with
rKSHV.219, and puromycin used to select stable transductants — but
again, no stable puromycin-resistant lines emerged. Next, in search of
more subtle phenotypes linked to KSHV infection, we examined each
cell type in the culture for GFP expression as a function of time
following infection in 6 independent infections of different tonsils
(Fig. 3). Without PHA pre-stimulation, the proportion of GFP+ CD4+
T cells (expressed as a percentage of the total number of CD4 cells) at
day 13 post-infection was signiﬁcantly lower than that at day 2: 3.4%
Fig. 1. Ex vivo tropism of rKSHV.219 in human lymphoid aggregate culture. (A) 2×106 homogenated tonsillar cells were pre-treated with PHA (10 μg/ml) for 12 h and infected with
1.5*106 infectious units (IU) rKSHV.219 for 48 h (MOI=0.7), after which cells were stained with either anti-CD19 (top panels) or anti-CD3 antibodies (bottom panels). KSHV
infectivity in each cell type was determined by examining GFP expression by ﬂow cytometry. (B) 2×106 tonsillar cells were either treated or untreated with PHA (10 μg/ml) for 12 h.
Cells were infected at MOI 0.04 for 48 h with subsequent staining with anti-CD3, anti-CD4, and anti-CD8 antibodies. KSHV infectivity in CD4+ or CD8+ T cells was analyzed in live
CD3+ cells. A representative plot (n=14) is shown.
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declined from being 16.7% of the initial CD8 population to 5.2% on day
13. By contrast, at day 13 PI, the percentage of GFP+ B cells was
signiﬁcantly higher compared to that at day 2: 4.6% vs 14%
(p=0.0009). The overall viability of uninfected HLAC cultures was
30–50% at day 2 p.i. andwaned to 5–10% at day 13, without changes in
B/T cell ratio (data not shown). These data could suggest that KSHV
infection provides a transient survival advantage in infected B cells(see Discussion). However, this extension of survival is not indeﬁnite,
at least in vitro: by day 60 p.i. most infected tonsillar cells were dead.
PHA pre-stimulation increased KSHV infectivity in T cells on day 2
(Fig. 4; cf. also Fig. 2). However, levels of GFP+ T cells at day 13 were
signiﬁcantly lower and furthermore, their levels were reduced to the
levels of cells without PHA pre-stimulation at day 13 p.i., suggesting
that PHA enhances susceptibility of T cells to KSHV infection, but not
the survival of infected T cells. Not unexpectedly, PHA pre-treatment
Fig. 2.Reproducibility of rKSHV.219 infectivity in tonsillar B and T cells. Tonsillar cellswere
left untreated or treated with PHA (10 mg/ml) for 6–12 h prior to virus infection
(MOI=0.04). Virus infectivity in various cell types was determined at 48 h post-infection
by examining GFP expression by ﬂow cytometry. Each dot represents rKSHV.219
infectivity in each cell type from individual tonsils. Mean of 10 independent experiments
is provided. Statistical analysis was performed by Student t-test.
Fig. 4. Cytokine-rich supernatants from activated T cells cannot enhance KSHV infection
of tonsillar T cells or B cells. Culture supernatants frommock-, PHA- or MLR-stimulated
cells were collected at the indicated time points (1–4 days post-stimulation) and used
as conditioned medium after ﬁltered through 0.2-μm nylon ﬁlter. Cells from fresh
tonsils were treated with medium, PHA (10 μg/ml) or conditioned medium, added at
40% v/v, for 24 h and washed extensively before virus infection. At 48 h post-infection,
cells were stained and virus infectivity was analyzed on ﬂow by assessing GFP
expression in CD4+ (A), CD8+ (B), or CD19+ (C) cells. One representative data of 3
independent experiments is shown.
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cells.
Activation signals that enhance lymphocyte infection
It is very surprising that T cells are, in general, more susceptible to
KSHV entry (and GFP expression) than B cells, and that their infection
is signiﬁcantly enhanced by PHA treatment (Figs.1 and 2). Time-
course experiments (data not shown) indicate that PHA enhancement
of KSHV infectivity in T cells is very rapid; treatment for as little as 2 h
results in near-maximal infectivity enhancement. The fact that the
extent of GFP expression in B cells in mixed HLAC cultures was
unaffected by PHA stimulation of T cells suggested that T cells
activated in this fashion were not producing soluble mediators that
inﬂuence KSHV entry into B cells. This inference was sustained by
studies in which HLAC cultures were pretreated with conditioned
medium from PHA-treated tonsillar cells, then exposed to rKSHV.219.
As shown in Fig. 4, no enhancement of viral entry and GFP expression
was seen in either B or T cells by PHA-conditioned medium. These
results also suggest that the stimulation of T cell infectivity by PHA is
largely cell-autonomous.
We also examined whether a still more potent T cell activation
reaction could generate paracrine factors thatmight affect lymphoid cell
infectivity. Accordingly, we set up a mixed lymphocyte reaction byFig. 3. GFP+ B cells are enriched in human lymphoid aggregate culture at later stage of
infection. Tonsillar cells were treated with PHA and infected as described in Fig. 2.
Infected culture was examined by ﬂow cytometry for GFP expression in each cell type at
day 2 and day 13. Mean of 6 independent experiments is provided. Statistical analysis
was performed by Student t-test.admixing HLAC cultures from two unrelated donors, then used
conditioned medium from such co-cultures to pretreat uninfected
tonsil cells; these cells were then exposed to rKSHV.219. Assays of the
MLR supernatants for IL-2 afﬁrmed that a robust MLR had indeed
occurred (datanot shown). Again, however, no stimulation of viral entry
and GFP expression was observed in either B or T cells under these
conditions (Fig. 4). Furthermore, MLR-stimulated cells themselves did
not show higher susceptibility to KSHV entry (data not shown).
Next, we asked if stimuli that activate B cells could increase the
susceptibility of the B cells in HLAC cultures to KSHV infection
(Rappocciolo et al., 2008). However, we found that pretreatment of
tonsillar cellswith,monomeric CD40L (≤10 μg/ml) aloneormonomeric
CD40L in combination with IL-4 (≤50 ng/ml) had no effect on the
proportion of B cells expressingGFP after KSHV exposure (Suppl. Fig. 1),
despite clear upregulation of CD86 by these treatments (data not
shown). LPS treatment of tonsillar HLAC cultures similarly failed to
enhance B cell infectivity (data not shown).
Finally, we asked whether KSHV-infected T cells display upregulation
of activation markers. To examine whether KSHV infection in T cells up-
regulates CD69 (immediate early activation marker) and CD25 (early
activation marker), infected tonsillar cells were gated for CD4+ (Figs. 5A
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(Figs. 5A and B) or CD25 (Figs. 5C and D) was examined by ﬂow
cytometry. One representative FACSplot is shown.Of note,mock-infected
CD4+ and CD8+ T cell populations showed CD69 expression on their
surface inmanycells even in the absenceof PHApre-treatment: 46.3%and
20.1%, respectively. This reﬂects the fact that tonsillectomies are only
performed on patients with hyperplastic (i.e. activated) tonsils. Nonethe-
less, CD69 expression was detected in still larger numbers of KSHV-
infected (GFP+) CD4+ and CD8+ (middle panels) T cells compared to
their uninfected (GFP−) counterparts (top panels): 67.8% vs 36.5%
(CD4+ T cells) and 49.5% vs 8.45% (CD8+ T cells). As expected, PHA
pre-treatment signiﬁcantly increased surface expression of CD69 and
CD25 (Fig. 5, right panels). KSHV infection in CD4+ and CD8+ T cells
further enhanced CD69 and CD25 expression on target cells, indicating
that T cells undergo activation following infection by KSHV.
Infected mixed (T+B) cultures, but not isolated T cells, support the full
replicative cycle of KSHV
Since the preceding experiments scored only for GFP expression,
they effectively only measure viral entry, uncoating and delivery ofFig. 5. rKSHV.219 infection activates susceptible T cells. Tonsillar cells were treated and infec
At 48 h post-infection, CD3+ T cells were gated and expression of activation markers, CD69 (
by ﬂow cytometry. GFP− or GFP+ cells were gated for the expression of activation markerthe viral genome to the nucleus; they do not examine whether such
cells can undergo lytic replication. To analyze whether such cells can
be lytically reactivated, PHA-treated tonsillar cells were infected at
MOI 0.1 for 6 h. After extensive wash, lytic replication was induced by
valproic acid (300 μM). At 5 days post-induction (Fig. 3A), induced
supernatants were collected and tested for infectious virus on
QBI293A cells, as assayed by enumeration of GFP-positive cells.
Infectious units were calculated by multiplying the percentage of
GFP+ cells by the number of total cells (Fig. 6A). When infected cells
were induced in the presence of valproic acid, signiﬁcantly higher
levels of infectious units were detected (p=0.046), suggesting that
latent infection in lymphocytes was reversible and that the lytic cycle
could progress to completion, with the production of infectious
progeny virus.
To further understand the extent of lytic reactivation of rKSHV.219
from infected tonsillar cells, infected PHA-treated tonsillar cells were
reactivated by various stimuli, such as PMA, PMA plus ionomycin,
PHA, and increasing amount of valproic acid (Fig. 6B). Culture
supernatants were harvested, treated with DNase I to remove
nonencapsidated DNA and examined by quantitative real-time PCR
for virion DNA. Each of these stimuli resulted in enhanced virionted. Cells were mock infected (top panels) or infected with rKSHV.219 (bottom panels).
A and B) or CD25 (C and D), in CD4+ (A and C) or CD8+ (B and D) T cells was analyzed
s in each cell type. A representative plot out of 4 independent experiments is shown.
Fig. 5 (continued).
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Comparison of the viral DNA copy number with the titer of infectious
virus produced under these circumstances leads us to estimate a
particle: infectivity ratio of ca. 2000:1— a number similar to that seen
in unpuriﬁed stocks of other herpesviruses (Benyesh-Melnick et al.,
1966; Dargan et al., 1995), but which is somewhat higher than
observed for rKSHV.219 grown in adherent Vero or SLK cells (particle:
infectivity ~800; J.M, unpublished data).
In addition to its constitutive GFP marker, rKSHV.219 also carries
an RFP gene under the control of a delayed–early lytic promoter (for
PAN). As such, lytic reactivation in most cultured cells is accompanied
by RFP expression. However, it is interesting to note that tonsillar cells
infected with rKSHV.219 did not show increase in RFP expression
following lytic induction with valproic acid (Suppl. Fig. 2). We do not
know the reason for this behavior; some possibilities include that
transcription, RNA processing or translation of the chimeric RFP
reporter gene is weak or aberrant in lymphoid cells, or the resulting
mRNA or protein is unstable in the presence of lytically replicating
virus.
Since the ability of T cells to support entry was unexpected, we
asked if isolated T cells (puriﬁed away from B cells) could support lytic
virus replication following infection. We infected either a mixed(T+B) culture or a pure T cell culture with rKSHV.219, washed away
free inoculum, then examined culture supernatants for infectious
KSHV, before and after valproate induction (Fig. 7). As shown in Fig. 7,
under conditions in which the mixed (T+B) culture showed
valproate-inducible infectivity, puriﬁed T cells released no infectious
virus. We conclude that the infection of T cells by KSHV is abortive,
with one or more post-entry blocks preventing the release of
infectious virions. By inference, the infectious virus released by the
mixed culturemust be coming from infected B cells. We have afﬁrmed
this inference by direct examination of infection of puriﬁed primary B
cells; these experiments revealed robust production of KSHV by B
cells (Fig. 7). Interestingly, this replication was not further enhanced
by valproate, suggesting that lytic replication of KSHV in B cells is
either constitutive, or that reactivation from latency in isolated B cells
is very efﬁcient. The fact that spontaneous production of KSHV
infectivity in the mixed culture is limited (Fig. 7) suggests that
reactivation is regulated in a complex fashion by T cells; this
regulation is the subject of a detailed study to be published elsewhere
(Myoung and Ganem, submitted). Consistent with this, quantitative
RT-PCR analysis reveals that infected T cells harbor only very low
levels of v-cyclin mRNA and no detectable ORF 59 mRNA (a classical
marker of lytic infection), even after lytic induction; by contrast,
Fig. 6. Infected tonsillar cells support full replication of rKSHV.219. (A) Tonsillar cells
were treated with PHA (5 μg/ml) for 12 h and infected with rKSHV.219 at MOI 0.1 for
6 h. Cells were extensively washed with warm complete media and induced with
valproate (300 μM) for 5 days. 100 μl of induced culture supernatants was added on
1×105 QBI293A cells and cultured for another 48 h before infectious units were
determined by enumerating GFP+ cells by ﬂow cytometry as described in Materials
and methods. Histograms represent mean (±SD) from 3 independent experiments.
Statistical analysis was performed by Student t-test. The dotted line denotes detection
limit. (B) Infected tonsillar cells as described in panel A were induced with various
stimuli as indicated for 5 days. Viral DNA was extracted from 100 μl induced culture
supernatant and used as template for real-time PCR. Histograms represent mean (±SD)
of duplicated samples. A representative plot is shown from 2 independent experiments.
Val denotes valproic acid.
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ORF 59 mRNA (Fig. 8). To further afﬁrm the defective nature of
infection in T cells, we examined transcription in such cells more
extensively, by hybridizing labeled RNA from infected T cells to a
custom KSHV genomic tiling array whose sequences span the entireFig. 7. Mixed cultures, but not puriﬁed T cells, support production of infectious virus.
CD3+ T cells or CD19+ B cells were isolated as described in Materials and methods.
Mixed, CD3+ T, or CD19+ B cells were infected with rKSHV.219 for 6–12 h and infected
cultures were left untreated or induced with valproic acid (300 μM) for 5 days. 100 μl of
culture supernatants was infected on QBI293A cells by low speed centrifugation
(2000 RPM for 90 min). GFP+ 293 cells were enumerated by FACS at day 2
post-infection and infectious units (IU) were calculated by multiplying total number
of 293 cells by the percentage of GFP+ cells in a given culture. Data from 3 individual
tonsils are plotted with standard deviation. VAL denotes valproic acid and the dotted
line indicates detection limit.KSHV coding region (save for the noncoding terminal repeats). As
shown in Fig. 8B, no detectable transcription was observed by
expression proﬁling in infected primary T cells; as a positive control
for the extraction and hybridization procedures, induced PEL cells
displayed robust viral transcription, as expected.
Discussion
The inability of KSHV to infect established lymphoblastoid cell
lines in culture has been a major impediment to the study of the
pathogenesis of the several lymphoproliferative diseases linked to this
virus infection. To date, we are aware of only a single report of
infection by KSHV of primary lymphoid elements (Rappocciolo et al.,
2008). That study focused primarily on peripheral blood B cells
pre-puriﬁed from other mononuclear cells prior to infection. It
showed that resting B cells were poorly infectable, but that
susceptibility was enhanced by B cell activation. While our results
do not directly address the role of B cell activation in KSHV infection,
they are certainly compatible with the notion that the activation state
of the B cell contributes to infectivity, since all our cells are derived
from tonsils with reactive hyperplasia in vivo. Taken together, these
two studies indicate that the longstanding barrier to growth of KSHV
in lymphoid cells has now been overcome. The question before the
ﬁeld now is: what can these systems tell us about KSHV infection of
these cells?
Our work establishes several new ﬁndings that raise interesting
questions about KSHV infection in the lymphoid compartment. First,
only a subset of B cells (typically 5–10%) can be infected ex vivo
(cf. Figs. 2–4). Even though we were limited (by the modest
achievable titers of rKSHV.219) to infections at MOI=0.7 or less,
this number is well below the expected level of infection (~50%)
under such conditions, assuming all B cells in the culture are equally
susceptible. Why do relatively few B cells become infected? Of course
it is possible that this merely reﬂects the absence of some important
condition or cofactor from our growth media. Alternatively, and
perhaps more interestingly, it may be that only certain subpopula-
tions of B cells are truly susceptible to KSHV infection. It seems
unlikely that activation state alone accounts for this result, since we
observed no further enhancement of infection in the presence of
powerful activators like LPS (data not shown) or CD40L plus IL4
(Suppl. Fig. 2). We are currently examining cellular mRNA expression
proﬁles and cell surfacemarkers in the GFP-positive and GFP-negative
B cells that emerge post KSHV infection, in an effort to shed light on
phenotypic differences that might relate to susceptibility.
Despite their relatively modest numbers, KSHV-infected B cells are
the only infected elements to be enriched in number after 2 weeks in
culture (Fig. 3). We do not know the basis of this phenomenon, which
could reﬂect reduced sensitivity to apoptosis or the spread of
infectious virus from infected B cells to other B cells in the culture.
The abundant production of virus by infected B cells (Fig. 8) might
favor the latter explanation. Even if there is a survival advantage in
culture, however, it is transient, and no immortalization in infected
tonsillar B cells is observed — in contrast to the powerfully
immortalizing effects of the EBV latency III program, which leads to
the regular and reproducible outgrowth of immortalized B lympho-
blasts from PBMCs (Altmann et al., 2006; Faumont et al., 2009; Martin
and Gutkind, 2008). A third possibility is that infected B cells may
undergo limited rounds of proliferation, as B cells display activated
phenotype upon infection (unpublished observations). However,
even if this is the case, the transient increase in numbers of infected
B cells is ultimately offset by B cell death in culture (Suppl. Fig. 3).
Theminimal phenotype of infected B cells in culture is consistentwith
everything we know about KSHV infection in humans. For example, no
clinical syndrome of lymphoproliferation is regularly linked to primary
KSHV infection in vivo (Ganem,2006), in contrast to thedramatic illnessof
mononucleosis induced inmany adults experiencing primary infectionby
Fig. 8. Viral gene expression in infected lymphocytes. (A) Mixed or puriﬁed cells were prepared, infected, and induced as described in Fig. 7. At day 2 and day 4 post-induction, induced
infected cultures were harvested and total RNA was extracted with 50 μl of RNA used for cDNA synthesis using gene-speciﬁc primers. Quantitative real-time PCR was performed as
described inMaterials andmethodswith plasmids containing eachgeneusedas standardcontrol.Dataplottedare from3 individual tonsils. Statistical signiﬁcancewas analyzedbyStudent
t-test. (B) Viral gene expression proﬁle in puriﬁed T cells, either uninfected (lane 1) or infected (lane 2), was assessed by microarray analysis. RNA was extracted from T cells at day 2
post-infection. Array analysis was done as described in Materials and methods. Zero-transformation was done against uninfected T cells. For comparison, RNA was extracted from either
BJAB cells (lane 3) or induced BCBL-1 (lane 4) at day 2 post-induction by valproate (600 μM). Zero-transformation was done against BJAB cells. KSHV tiling microarray data (ordered by
genome position) are displayed for 13,444 unique probes. The color bar indicates the fold change relative to the level for the uninfected T cells or BJAB cells.
8 J. Myoung, D. Ganem / Virology 413 (2011) 1–11EBV (Thorley-Lawson, 2001; Thorley-Lawson and Gross, 2004). Similarly,
latent infection of endothelial cells in KS produces an indolent lesion in
immunocompetent hosts, with few fatalities, long periods of relative
quiescence (Ganem, 2006), and even occasional spontaneous remissions
(Gambassi et al., 2005; Lospalluti et al., 1995). Cells cultured from KS
lesions typically are not transformed, display enhanced rather than
reduced sensitivity to exogenous growth factors (Ensoli et al., 1989, 2001;
Ensoli and Sturzl, 1998), and are nontumorigenic in nude mice (Ensoli
et al., 1994; Ensoli and Sturzl, 1998; Fiorelli et al., 1995). Thus, nothing in
the human biology of KSHV infection should lead us to expect a dramatic
in vitro phenotype in latency. Nonetheless, we acknowledge that KSHV
infection is indeed linked tovery rare lymphoproliferative diseases in vivo,
andnote thatour results areentirelybasedoncell cultures,whichmaynot
reproduce the conditions necessary for B cell immortalization.
Perhaps the most surprising result to emerge from this work was
that T cells were very efﬁciently infected ex vivo (Figs. 1, 2, 4 and 5)—
in fact, a greater proportion of T cells than B cells became KSHV
positive, despite their smaller absolute numbers in the culture. Both
CD4 and CD8 subsets are infectable, and infectivity was substantially
enhanced by T cell activation in a cell-autonomous fashion (Figs. 1, 2,
and 5), implying that signaling within the activated cell was
responsible. However, these infected T cells display very minimal
KSHV gene expression (Fig. 8) and do not produce infectious viral
progeny (Fig. 7), indicating that infection is abortive. These data
indicate that GFP expression driven by the constitutive cellular
promoter (EF1α) does not always serve as an accurate indicator of
genuine KSHV latency. The fact that very little authentic KSHV latentgene expression proceeds in infected T cells suggests that either (i) T
cells lack permissive factors for KSHV latent promoters; or (ii) T cells
actively repress latent viral gene expression, at either the genetic or
epigenetic level. Additionally, post-transcriptional mechanisms (e.g.
accelerated viral mRNA turnover) could also be operating on some
transcripts. Further work will be required to sort out these
mechanisms in detail. Obviously, these factors are not mutually
exclusive, and identiﬁcation of blocks to viral transcription in T cells
could shed light on novel forms of host regulation of viral gene
expression that inﬂuence KSHV tissue tropism.
What is the signiﬁcance of tonsillar T cell infection? Most studies of
KSHV tropism,whichhave focusedon thedistributionofKSHVgenomes
in cell populationspuriﬁed fromPBMCs, have concluded that infection is
limited to CD19+B cells, and possibly tomonocytes (Blasig et al., 1997;
Wu et al., 2006). Similar conclusions have been drawn from limited
studies of lymph nodes from patients with MCD (Dupin et al., 1999).
Moreover, it is important to acknowledge that many prior studies of in
vitro infection by KS have noted infection of cell types in culture that are
not infected in vivo. For example, ﬁbroblasts and keratinocytes are
readily infected by KSHV in vitro (Bechtel et al., 2003; Cerimele et al.,
2001; Renne et al., 1998), but studies of dermal KS show KSHV antigens
localized only to endothelial cells, and not in ﬁbroblasts or epithelium
(Boshoff et al., 1995a; Ganem, 2006;Herndier andGanem, 2001). So it is
entirely possible that our ﬁnding that T cells can support viral entry is
merely another example of this phenomenon—whosemolecular basis,
parenthetically, remains a mystery. However, since tonsillar T cell
infection is clearly abortive, secondary spread of virus among T cells is
9J. Myoung, D. Ganem / Virology 413 (2011) 1–11predicted to be negligible, whichmay likewise account for the negative
studies in peripheral blood and secondary nodes distal to the portal of
entry of KSHV.
Interestingly, there are hints from the human biology of KSHV
that the virus can enter T cells in vivo. The most compelling of
these are three reports of T cell lymphomas in which KSHV DNA
was found; all were PEL-like in that they originated from body
cavities (Coupland et al., 2005; Lechapt-Zalcman et al., 2001; Said
et al., 1999). Although rare, the existence of such tumors bears
witness to the fact that T cell infection can occur in humans, at least
at a low level. In addition, Harrington et al. (1996) demonstrated
that T cells puriﬁed by immune-magnetic beads from PBMC of a
KS patient are infected by KSHV, albeit to a lesser degree than B
cells. These results were conﬁrmed by an independent group
(Sirianni et al., 1997), who showed that clonal TCR αβ+ CD8+ T
cells, derived from 3 patients, harbored KSHV genomeswhen assessed
by nested PCR (Boshoff et al., 1995b). Furthermore, these KSHV-
infected CD8+ T cells were functional in terms of cytokine release
(e.g., interferon-γ production). Thus, while it is likely that the ex vivo
HLAC system exaggerates the susceptibility of T cells to KSHV
compared to infection in vivo, these results suggest that the
conventional wisdom that T cells are never targets of KSHV may be
an oversimpliﬁcation.Materials and methods
Cells and human lymphoid aggregate culture (HLAC)
QBI293A cells, a subcloned 293 cell line, were purchased from
Q-Biogene (Carlsbad, CA) for the titration of rKSHV.219 stocks. Stable
Vero cells, harboring rKSHV.219 genome, were a kind gift from Dr.
Jeffrey Vieira (Vieira and O'Hearn, 2004). Following approval from the
UCSF Committee on Human Research, tonsillar tissue from routine
tonsillectomies was obtained (via the Cooperative Human Tissue
Network) and processed for HLAC as described previously (Eckstein
et al., 2001; Kreisberg et al., 2006). In brief, tonsils were minced in a
tonsil medium (RPMI 1640 supplemented with 15% FCS, 100 μg/ml
gentamicin, 100 μg/ml ampicillin, 1 mM sodium pyruvate, 1% nones-
sential amino acids (Mediatech), 2 mM L-glutamine, and 1% fungizone
(Invitrogen)). Tonsil blocks were passed through a 40-μm cell
strainer, and cultured in 96-well U-bottomed polystyrene plates
(2×106 cells/well) in tonsil medium (200 μl/well).Reagents and antibodies
All antibodies were purchased from Biolegend except streptavi-
din-QDot 605 (Invitrogen). Lyophilized PHA was purchased from
Sigma and reconstituted in PBS and aliquots were stored at −80 °C.
All cytokines including monomeric CD40L, IL-4, and IL-10 were
purchased from Peprotech.Cell puriﬁcation using magnetic beads
Untouched B or T cells were isolated negatively by employing B
cell isolation kit II and Pan T cell isolation kit II, respectively, according
to the manufacturer's instruction. Brieﬂy, 108 cells were labeled with
100 μl of biotin-antibody cocktail for 10 min at 4 °C followed by 200 μl
of anti-biotin MicroBeads for 15 min at 4 °C. Unwanted cells were
removed through a column and eluents were washed twice in tonsil
medium before use. When required, CD4+ or CD8+ T cells were
positively selected by CD4 and CD8 T MicroBeads, respectively. All
reagents used for cell puriﬁcation were purchased from Miltenyi
Biotec.Virus preparation
rKSHV.219 stocks were prepared from stable Vero cells as
described elsewhere with minor modiﬁcations (Vieira and O'Hearn,
2004). Brieﬂy, stable Vero cells were infected with recombinant
adenovirus expressing RTA (Bechtel et al., 2003) at MOI 100 in a
minimum volume for 2–3 h before wash. Cells were then induced for
22 h with 1200 μM valproate. The medium with valproate was
removed and fresh DMEM without puromycin but supplemented
with 2% FBS and penicillin and streptomycin, was added. Induced cells
were further cultured for another 72 h before culture supernatant was
collected. Virus was puriﬁed as described previously (Grossmann and
Ganem, 2008). In brief, supernatants were cleared of cells by
centrifugation (2000 RPM for 10 min) with subsequent ﬁltration
through a 0.45 μm ﬁlter, and the virions were pelleted at 27,000 ×g for
2 h. Viral pellets were resuspended in 1/125 of the original volume
using tonsil medium. Infectious units (IUs) of virus stocks were
determined on QBI293A cells as described previously (Vieira and
O'Hearn, 2004). Brieﬂy, virus stock was serially diluted and infected
into QBI293A cells for 6 h in a 24-well plate. After fresh media was
added, cells were further cultured for 48 h before the percentage of
GFP+ cells was determined by FACS Calibur. IUs were calculated by
multiplying the percentage of GFP+ cells by the total number of
QBI293A cells in a well at the time of ﬂow cytometric analysis.Stimulation of tonsillar cells and virus infection
2×106 tonsillar cells were stimulated with PHA (Sigma) for various
duration of time and washed extensively before use. PHA-stimulated
cells were infected at MOI 0.2–3 in a 96-well U-bottomed plate in total
200 μl/well for 48 h before cells were stained for ﬂow cytometric
analysis (1 MOI is deﬁned by 1 IU per cell). To examine effects of
inﬂammatory cytokines and immunomodulatory molecules on KSHV
infectivity in B cells, 2×106 tonsillar cells were stimulated by
monomeric soluble CD40L (sCD40L), IL-4, IL-10 or in combinations for
24 h prior to virus infection. Cells were washed extensively before use.Conditioned medium from PHA- and mixed lymphocyte reaction
(MLR)-stimulated tonsillar cell cultures
Tonsillar cells were stimulated with PHA (10 μg/ml) for 12 h and
washed extensively in complete tonsil medium. Cells were further
cultured in fresh medium and culture supernatants were collected
and stored at−20 °C until use after ﬁltration through a 0.45-μm ﬁlter.
To obtain MLR-stimulated culture supernatants, tonsillar cells from
two different individuals were mixed: 5×106 responder cells were
mixed with 2.5×106 stimulator cells. Culture supernatants were
collected at various times and kept at−20 °C until use after ﬁltration
through a 0.45-μm ﬁlter. To conﬁrm that PHA- and MLR-stimulated
culture supernatants contain immuno-modulatory molecules (cyto-
kines, chemokines, etc.) from activated immune cells, levels of IL-2
were assessed using ELISA MAX® kit for human IL-2 (Biolegend).
Conditioned media were added at v/v 40% to fresh tonsillar cultures
for 24 h prior to viral infection.Flow cytometry
rKSHV.219-infected tonsil cells were stained with antibodies for
30 min at 4 °C. Cells were washed twice with 1 ml PBS containing 4%
FBS before ﬁxed with 1% paraformaldehyde. Fixed cells were washed
twice with PBS and resuspended in PBS/4% FBS. Stained cells were
analyzed on FACS Calibur or LSR II (Beckton Dickinson). FACS data
were analyzed using FlowJo software.
10 J. Myoung, D. Ganem / Virology 413 (2011) 1–11Viral DNA extraction and quantitative real-time PCR
Viral DNA was extracted from culture supernatants as described
previously (Grossmann and Ganem, 2008). In brief, culture super-
natantswere collected from induced cells andﬁltered througha0.45 μM
ﬁlter. To remove free viral DNA in the medium, 20 U/ml DNase I was
added and incubated at 37 °C for 1 h. Virions were pelleted down at
27,000 ×g for 2 h at 4 °C. Virus pellet was resuspended in 600 μl lysis
buffer (20 mM Tris–HCl at pH 8, 10 mM EDTA, 100 mM NaCl, and 0.5%
SDS) and incubated at room temperature for 10 min. 0.7 mg/ml
Proteinase K and linearized plasmid encoding an unrelated malaria
gene (cysteine protease gene of Plasmodium falciparum) were diluted in
100 μl lysis buffer and added to the 600 μl resuspended virions. The
700 μl total volume was incubated at 37 °C overnight; this was then
extracted with phenol/chloroform/isoamyl. Viral DNA was precipitated
and resuspended in 85 μl of water. 2 μl of this was used in the
subsequent Taqman and Sybergreen assays for PAN promoter and
spiked-in malaria gene as a normalizing factor as described previously
(Grossmann and Ganem, 2008) using BAC36 as a standard (Zhou et al.,
2002). Taqman (for Pan promoter) and Sybergreen (for malaria DNA)
reactions were performed in triplicates using Taqman Universal Master
Mix (Applied Biosystems) and SybergreenER mastermix (Invitrogen),
respectively, according to the manufacturer's instructions.
RNA extraction and quantitative real-time PCR
Total RNA was extracted from 2*106 cells by RNA-Bee (Tel Test Inc.,
TX) according to the manufacturer's instruction. 50 ng of total
RNA, treated with DNase I, was used to synthesize cDNA using
gene-speciﬁc primers for ORF59 and vCyclin. Primers used were
as follows: ORF59, forward: 5′-GTTTACCCCCGGGCTGAT-3′, reverse:
5′-GGGCACACCTTCCACTTCTAAT-3′, probe: 5′-FAM-TGGCACTCC-
AACGAA-MGB-3′; vCyclin, forward: 5′-CGCGGCATAGCAAAGTGAA-3′,
reverse: 5′-GCCTGTTAGTGGCCAGTAAGCT-3′, probe: 5′-FAM-TGGTA-
GAAATAGGCGTGAGGCTTCT-MGB-3′. Reverse primers were used to
generate gene-speciﬁc cDNA in reverse transcriptase reactions using
SuperScript® III Reverse Transcriptase (Invitrogen, CA). Quantitative real-
time PCRwas done on each cDNA by empolying TaqMan®Universal PCR
master mix from Applied Biosystems with plasmids encoding each gene
as a standard according to the manufacturer's instruction.
Microarray analysis on viral gene expression in infected T cells
Total RNA was extracted from tonsillar cells using RNA-Bee (Tel-
Test, Inc.) after a wash with cold incomplete PBS according to the
manufacturer's protocol. Tonsillar RNAs were repuriﬁed twice using
the RNeasy minikit (QIAgen) according to the manufacturer's
instruction. The quality of the puriﬁed RNAs was analyzed using the
RNA 6000 Pico total RNA kit and the 2100 Bioanalyzer (Agilent). All
RNA samples displayed RIN value of at least 9, which indicates good
integrity of RNAs, and RNA samples were quantiﬁed using the ND1000
spectrophotometer (nanodrop). Labeled cRNA from 250 ng of total
RNAwas generated using the two-color Quick Amp Labeling (Agilent)
according to the manufacturer's protocol. Experimental samples
(labeled with Cyanine 5-CTP) and reference samples (labeled with
Cyanine 3-CTP) were competitively hybridized to custom KSHV
microarrays (Agilent) according to the manufacturer's instruction.
Cyanine 3-CTP and Cyanine 5-CTP were purchased from Perkin Elmer.
Hybridizations and washes were conducted according to the
manufacturer's protocol. Washed arrays were scanned using the
GenePix 400B Scanner (Axon Instruments) and feature intensities
extracted using GenePix Pro 6.0 software. TIFF images of scanned
slides were analyzed using the Feature Extraction Software, Ver 9.5.3
(Agilent). A graphical presentation of processed data (heat map) was
generated by Java Treeview.Statistical analysis
Data are shown either as the means±standard deviations (SD) of
at least three independent experiments or as one representative
example from at least three independent experiments. The signiﬁ-
cance of differences in the mean values was determined by the
Student's t test. Pb0.05 was considered statistically signiﬁcant.
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.virol.2010.12.036.
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